 The study compares the cost-effectiveness of Brodalumab, a newly approved biologic drug for psoriasis treatment, with other commonly used biologics in the US. An economic model was constructed to estimate total annual costs and mean annual treatment costs for POSI 75, 90 and 100 among moderate to severe psoriasis patients treated with five different biologics. Results show that Brodalumab had the lowest drug cost and highest drug efficacy, leading to the lowest cost per POSI 75, 90 and 100 among the biologics evaluated. This article was authored by Jaixin J. Wu, Stephen R. Feldman, Shipra Rastogi, and others.